MYCN and prostate cancer: It promotes glutamine uptake by activation of glutamine transporters SLC1A5 and SLC38A5. 41 In human P-493 B lymphoma cells and PC3 prostate cancer cells, MYC transcriptionally inhibits miR-23a/b to enhance the translation of GLS1 (encodes glutaminase 1, also called GLS), leading to elevated glutaminolysis.26 Moreover, MYCN promotes glutaminolysis via selective activation of GLS2 (encodes glutaminase 2), but not GLS1, transcription in MYCN-amplified neuroblastomas.42,43 Most likely, MYC regulation of glutaminolysis strictly depends on tumor context.